Prevention of osteoporosis-related fractures among postmenopausal women and older men

CMAJ. Canadian Medical Association Journal

Volumn 181, Issue 11, 2009, Pages 815-820

  Rahmani, Poupak ^a   Morin, Suzanne ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; BONE PAIN; CLINICAL EVALUATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FALLING; FEMALE; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HEADACHE; HIP FRACTURE; HOT FLUSH; HUMAN; HUMERUS FRACTURE; HYPERCALCEMIA; INFLUENZA; INJECTION SITE PAIN; JAW OSTEONECROSIS; LEG CRAMP; LIFESTYLE MODIFICATION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; REVIEW; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 72949117457     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.080709     Document Type: Review

References (80)

1. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-8.
2. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997;12:1761-8.
3. Adachi JD, Loannidis G, Berger C, et al. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 2001;12:903-8.
4. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-82.
5. Siris ES. Patients with hip fracture: What can be improved? Bone 2006;38:S8-12.
6. Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after lowtrauma fracture in men and women. JAMA 2007;297:387-94.
7. Gates S, Fisher JD, Cooke MW, et al. Multifactorial assessment and targeted intervention for preventing falls and injuries among older people in community and emergency care settings: systematic review and meta-analysis. BMJ 2008;336:130-3.
8. Gillespie LD, Gillespie WJ, Robertson MC, et al. Interventions for preventing falls in elderly people [review]. Cochrane Database Syst Rev 2003;(4):CD000340.
9. Kanis JA, Melton LJ III, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
10. Siris ES, Brenneman S, Barrett-Connor E, et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 2006;17:565-74.
11. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18:1033-46.
12. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3.
13. Langsetmo L, Hanley DA, Kreiger N, et al. Geographic variation of bone mineral density and selected risk factors for prediction of incident fracture among Canadians 50 and older. Bone 2008;43:672-8.
14. Taylor BC, Schreiner PJ, Stone KL, et al. Long-term prediction of incident hip fracture risk in elderly white women: study of osteoporotic fractures. J Am Geriatr Soc 2004;52:1479-86.
15. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral density reporting in Canada. Can Assoc Radiol J 2005;56:178-88. Available: www .osteoporosis .ca/index.php/ci-id/5921/index.php?ci-id= 5922&la-id=1 (accessed 2009 Sept. 22).
16. Nguyen ND, Frost SA, Center JR, et al. Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. Osteoporos Int 2008;19:1431-44.
17. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-97.
18. Leslie WD, Tsang JF, Lix LM. Validation of ten-year fracture risk prediction: a clinical cohort study from the Manitoba Bone Density Program. Bone 2008;43(4): 667-71.
19. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.
20. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167:S1-34.
21. Jamal SA, Leiter RE, Bayoumi AM, et al. Clinical utility of laboratory testing in women with osteoporosis. Osteoporos Int 2005;16:534-40.
22. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
23. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370:657-66.
24. Cranney A, Horsley T, O'Donnell S, et al. Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep) 2007;Aug:1-235.
25. Dawson-Hughes B, Tosteson AN, Melton LJ III, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008;19:449-58.
26. Stevenson M, Lloyd JM, De Nigris E, et al. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005;9:1-160.
27. Ytterstad B. The Harstad injury prevention study: the characteristics and distribution of fractures amongst elders - an eight year study. Int J Circumpolar Health 1999; 58:84-95.
28. Province MA, Hadley EC, Hornbrook MC, et al. The effects of exercise on falls in elderly patients. A preplanned meta-analysis of the FICSIT Trials. Frailty and Injuries: Cooperative Studies of Intervention Techniques. JAMA 1995;273:1341-7.
29. Siminoski K, Leslie WD, Frame H, et al. Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 2007;10:120-3.
30. Dawson-Hughes B. A revised clinician's guide to the prevention and treatment of osteoporosis. J Clin Endocrinol Metab 2008;93:2463-5.
31. Schwab P, Klein RF. Nonpharmacological approaches to improve bone health and reduce osteoporosis. Curr Opin Rheumatol 2008;20:213-7.
32. Park H, Kim KJ, Komatsu T, et al. Effect of combined exercise training on bone, body balance, and gait ability: a randomized controlled study in community-dwelling elderly women. J Bone Miner Metab 2008;26:254-9.
33. Rucker D, Allan JA, Fick GH, et al. Vitamin D insufficiency in a population of healthy western Canadians. CMAJ 2002;166:1517-24.
34. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293:2257-64.
35. Boonen S, Lips P, Bouillon R, et al. Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007;92:1415-23.
36. Papadimitropoulos E, Wells G, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 2002;23:560-9.
37. Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and postmenopausal osteoporosis [review]. Cochrane Database Syst Rev 2005;(3):CD000227.
38. Jackson C, Gaugris S, Sen SS, et al. The effect of cholecalciferol (vitamin D3) on the risk of fall and fracture: a meta-analysis. QJM 2007;100:185-92.
39. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006.
40. Davison KS, Siminoski K, Adachi JD, et al. The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. Semin Arthritis Rheum 2006;36:10-21.
41. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213.
42. Wells G, Cranney A, Boucher M, et al. Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a metaanalysis [Technology Report no. 69]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2006. Available: www.cadth.ca /index.php /en /hta /reports -publications /search/publication/659 (accessed 2009 Feb. 4).
43. Nguyen ND, Eisman JA, Nguyen TV. Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials. J Bone Miner Res 2006;21:340-9.
44. Wells GA, Cranney A, Peterson J, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women [review]. Cochrane Database Syst Rev 2008;(1):CD003376.
45. Boonen S, Laan RF, Barton IP, et al. Effect of osteoporosis treatments on risk of nonvertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005;16:1291-8.
46. Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508-16.
47. Papapoulos SE, Quandt SA, Liberman UA, et al. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005;16:468-74.
48. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women [review]. Cochrane Database Syst Rev 2008;(1):CD001155.
49. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008;(4):CD004523.
50. Cranney A, Tugwell P, Adachi J, et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:517-23.
51. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22.
52. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
53. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9.
54. Delmas PD, Recker RR, Chesnut CH III, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8.
55. Sawka AM, Papaioannou A, Adachi JD, et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005;6:39.
56. Tremaine WJ, Khosla S. Bisphosphonates and the upper gastrointestinal tract: Skeletal gain without visceral pain? Mayo Clin Proc 2002;77:1029-30.
57. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91.
58. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med 2007;356:1895-6.
59. Karam R, Camm J, McClung M. Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 2007;357:712-3.
60. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826-31.
61. Sorensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population-based case-control study. BMJ 2008;336:813-6.
62. Bisphosphonates marketed as alendronate (Fosamax, Fosamax Plus D), etidronate (Didronel), ibandronate (Boniva), pamidronate (Aredia), risedronate (Actonel, Actonel W/Calcium), tiludronate (Skelid), and zoledronic acid (Reclast, Zometa). Rockville (MD): US Food and Drug Administration; 2007. Available: www .fda .gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts /ucm150837.htm (accessed 2009 Sept. 22).
63. Shelly W, Draper MW, Krishnan V, et al. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008;63:163-81.
64. Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 2008; 11:325-38.
65. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:524-8.
66. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355: 125-37.
67. Cranney A, Tugwell P, Zytaruk N, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:540-51.
68. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76.
69. Toth E, Csupor E, Meszaros S, et al. The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures - an open label study. Bone 2005;36:47-51.
70. Knopp JA, Diner BM, Blitz M, et al. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 2005;16:1281-90.
71. Goltzman D. Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone. Arch Biochem Biophys 2008;473:218-24.
72. Cranney A, Papaioannou A, Zytaruk N, et al. Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ 2006;175:52-9.
73. Vestergaard P, Jorgensen NR, Mosekilde L, et al. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk - a meta-analysis. Osteoporos Int 2007;18:45-57.
74. Cranney A, Papaioannou A, Zytaruk N, et al. Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ 2006;175:52-9.
75. Kiel DP, Magaziner J, Zimmerman S, et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA 2007;298:413-22.
76. Sawka AM, Boulos P, Beattie K, et al. Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis. J Clin Epidemiol 2007; 60:336-44.
77. Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ 2006;332:571-4.
78. Sawka AM, Gafni A, Boulos P, et al. Could a policy of provision of hip protectors to elderly nursing home residents result in cost savings in acute hip fracture care? The case of Ontario, Canada. Osteoporos Int 2007;18:819-27.
79. Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporos Int 2008;19:1363-8.
80. National Osteoporosis Foundation. Physician's guide to the prevention and treatment of osteoprosis. Washington (DC): The Foundation; 2003.